Inside Drug Pricing - 11/04/2019

Verma Worried Outcomes-Based Rx Contracts Could Hike Launch Prices

By Rachel Cohrs / October 31, 2019 at 3:22 PM
CMS Administrator Seema Verma on Wednesday (Oct. 30) said CMS is pursuing policies to allow outcomes-based drug contracts to circumvent Medicaid best price requirements, but said she is concerned the arrangements could lead to higher launch prices for drugs. If drug makers understand that they would be giving discounts on drugs if the medicines do not produce certain patient outcomes, that calculation may be built into drugs’ base prices, Verma said. “I think we should be cautious on this. One...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.